Protara Therapeutics reports Q2 EPS (35c), consensus (38c)

“As we look toward the second half of the year, we believe we are well positioned to continue to advance our pipeline of potentially transformative therapies for the treatment of patients with cancer and rare diseases,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics (TARA). “We continue to execute on our ADVANCED-2 trial of TARA-002 in non-muscle invasive bladder cancer and look forward to presenting interim results in the first quarter of 2026. In addition, we remain on track to dose the first patient in our THRIVE-3 registrational trial of IV Choline Chloride in patients dependent on parenteral support by the end of this quarter and expect to provide an interim update from the STARBORN-1 trial in pediatric patients with lymphatic malformations in the fourth quarter of this year.”